You have found 219 entries after clicking on a search link (usually the MORE information link) in a matrix cell. Sorted by the main topic addressed, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.
Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the most recently added or updated entries or by the most recently published documents
If you have not found what you want you could:
Select from the full range of topics and search options available on our topic search page.
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or recent bulletins.
Documents are regularly added. Use the e-mail update service to monitor additions.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo
STUDY 2004 PDF file 607Kb
Opiate antagonist treatment risks overdose
The most comprehensive recent study of serious medical incidents during and after treatment for opioid dependence highlighted the risk of overdose death when patients stop taking opiate-blocking drugs. In comparison, substitute prescribing was safer even after the patient had left treatment.
STUDY 2006 PDF file 152Kb
Naltrexone implants prevent opiate overdose
Short-acting opiate blockers are associated with high overdose rates when heroin-dependent patients stop taking them. This Australian study suggests that a product intended to block opiates for six months can overcome that problem, though patients may resort to sedatives instead.
STUDY 2006 PDF file 108Kb
1 in a 100 chance of dying after treatment with heroin-blocking drug
In Australia heroin-addicted patients trying to avoid relapse by taking the opiate-blocking drug naltrexone had at least a 1 in a 100 chance of dying within three months, usually from overdose in the weeks after treatment ended; the true figure may have been as high as 8 in a 100.
In the first study of its kind opiate-dependent prisoners in Norway were randomly allocated to a six-month implant which blocks the effects of heroin or to methadone which substitutes for heroin as a way of bridging the period after release. Among the few interested in either option, they led to equivalent reductions in opiate use and crime.
STUDY 2010 HTM file
Favorable mortality profile of naltrexone implants for opiate addiction
Few treatments for opiate addiction arouse as much controversy as naltrexone implants. Inserted under the skin, these block the effects of heroin for up to several months - for some, a magic bullet, for others, an unsafe and ethically dubious experiment. More evidence from Australia that the overdose death risk is less than with oral forms of the drug.
From the USA’s professional society for clinicians and allied professionals in the field of addiction medicine, comprehensive recommendations on how doctors can use medications to treat addiction to heroin and other opioids.
In the first randomised trial, implants which block opiate-type drugs for months helped heroin addicts in Norway avoid relapse after detoxification. If these or allied products gain a UK licence, they could help pave the way to abstinence for the minority of suitable addicts.
DOCUMENT 2017 HTM file
Drug misuse and dependence: UK guidelines on clinical management
Last published in 2007, there is no more important document for UK clinicians involved in treating problem drug use than the so-called ‘Orange guidelines’. This major update offers detailed guidance on the range of problems, settings and patients clinicians encounter, substantially informing judgements of what constitutes good medical practice.
STUDY 2002 PDF file 155Kb
Drug users who continue to inject still respond well to hepatitis C treatment
UK guidance from NICE and the Department of Health on the treatment of hepatitis C infection may need to be revised in the light of studies showing that drug users who continue to inject can nevertheless respond well to the treatment.
European and US studies show that methadone patients stick with therapy for hepatitis C disease and do as well as other patients, bolstering the case for drug services to encourage clients to consider diagnostic testing and therapy.
Select search results pagePREVIOUS | NEXT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22